Press release
CROS NT WINS A "BEST PRESENTATION" AT PhUSE 2010
Verona, Italy (26 NOVEMBER 2010) – Stefano Vezzoli, part of CROS NT’s highly qualified and experienced biostatistics team, won Best Presentation in the area of Statistics and Pharmacokinetics at the Pharmaceutical Users Software Exchange (PhUSE) conference in Berlin, Germany. Vezzoli’s presentation was titled “Inference for the Location Shift in 3x3 Crossover Studies: the Median-Scaling Method”.Vezzoli’s Paper Abstract
In the case of non-normal study outcomes, a nonparametric approach may be used for the analysis. Willavize and Morgenthien proposed a nonparametric method to obtain point estimates and confidence intervals for the location shift between treatments in the specific context of a 3-treatment, 3-period, 6-sequence crossover design. This technique allows for the period effect by use of sequence stratification and median-scaling. The aim is to outline the rationale of the method and to present a SAS® macro to implement this approach based on the HL (Hodges-Lehmann) option of the NPAR1WAY procedure. Depending on the sample size, asymptotic or exact confidence limits can be calculated.
CROS NT was also represented at the PhUSE conference by Valeria Visonà, Head of Programming for Biostatistics, and Matteo Ferrari who presented a poster on “Data Migration from Oracle Clinical® to .XML using SAS®”.
For more information or to download CROS NT presentations from PhUSE 2010, please contact us.
CROS NT Group, an international Contract Research Organisation (CRO), with headquarters in Verona, Italy, has built a strong heritage in biostatistics as well as providing clinical data management, medical communication, pharmacovigilance, and technology solutions to the life science industry for over 18 years. Founded in 1992, CROS NT is well-established in delivering quality, timely delivery, and cost effective service. The Arithmos branch of CROS NT provides IT solutions to the pharmaceutical and biotechnology industries such as hosting, ePRO & eCRF and Project and Portfolio Management to reduce trial timelines and improve drug safety reporting.
CROS NT Group
Via Germania 2
37135 Verona ITALY
Contact: Mary Wieder, Marketing Officer
+39 045 820 26 66
mary.wieder@crosnt.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release CROS NT WINS A "BEST PRESENTATION" AT PhUSE 2010 here
News-ID: 153345 • Views: …
More Releases from CROS NT
CROS NT GROUP TO ATTEND THIRD ANNUAL ONCOLOGY CLINICAL TRIALS
Verona, Italy (23 NOVEMBER 2010) – The German subsidiary of the CROS NT Group, CROS DE GmbH, will be present at the Third Annual Oncology Clinical Trials in Munich, Germany from 29 November through 1 December. The therapeutic area of oncology is one of CROS NT’s areas of excellence regarding clinical trial experience, and the CROS DE management team is at the forefront of clinical trial consultancy in this field.…
CROS NT Group launches Arithmos s.r.l. to keeping up with the new Innovation’s …
CROS NT Group launches Arithmos s.r.l., a start up company created at the beginning of 2010 with the aim to play an active role as information technology service provider within the pharmaceutical and biotechnology environment.
Inheriting CROS NT’s 15 years experience and developing a strong sensibility for innovation investments, today Arithmos is a valuable partner to optimize companies performances and accelerate their growth into the market in an accurate, safe and…
CROS NT appoints new Vice President for Germany
CROS NT (CRO) announces the appointment of Frank Freischläger as Vice President (VP) for CROS DE GmbH, the German affiliate of CROS NT. As a VP at CROS DE he will be responsible for all aspects, which is focused on successful clinical trial activities.
CROS is very excited to adding Mr. Freischläger's depth of industry expertise to the CROS team. "Bringing someone of Frank's knowledge to an already strong team…
CROS NT Announces its Expansion into German Market Creating CROS DE GmbH
CROS NT is pleased to announce its expansion into Europe through the creation of CROS DE GmbH, a new wholly-owned subsidiary based in Augsburg, Germany. The company, born from the experience of a German-based CRO, Estimate GmbH, is specialized in providing statistical services to pharmaceuticals and biotechnology industries.
Estimate enrich CROS NT with its expertise and a particular excellence concerning the oncology and dermatology-related research. Estimate was found in 1992…
More Releases for CRO
Global Veterinary CRO & CDMO Market Size & Trends
According to a new market research report published by Global Market Estimates, the global veterinary CRO & CDMO market is expected to grow at a CAGR of 9.1% from 2023 to 2028.
The growing awareness regarding the importance of animal health and welfare has led to increased investments in veterinary pharmaceutical research and development. This awareness is driven by the rising concern for the well-being of pets, livestock, and animals used…
Global Contract Research Organization (CRO) Services Market
According to a new market research report published by Global Market Estimates, the Global Contract Research Organization (CRO) Services Market is expected to grow at a CAGR of 10.2% from 2023 to 2028.
The growth of the contract research organization (CRO) Services Market is fuelled by factors including the rising preference for outsourcing clinical trials, increasing investments in research and development by pharmaceutical and biopharmaceutical companies, the growing complexities in drug…
Contract Research Organization (CRO) Services Market - Efficiency, Expertise, Ex …
Newark, New Castle, USA: The "Contract Research Organization (CRO) Services Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors
Contract Research Organization (CRO) Services Market: https://www.growthplusreports.com/report/contract-research-organization-cro-services-market/7630
This latest report…
Biopharmaceutical CMO and CRO Market
The Biopharmaceutical CMO and CRO Market crossed US$ 32.25 billion in 2022 and is expected to hit US$ 54.13 billion by 2030, recording a CAGR of 6.5% during the forecast period
Pharmaceutical and biotech companies focus on R&D activities to innovate new molecules and therapeutic platforms to deal with chronic diseases and rare ailments; they also extensively invest in R&D activities to develop various therapeutic applications with strong medical and commercial…
Pracedo Promote Ellie Copp To CRO
Pracedo, a Mashfrog Group company that provides Salesforce consultancy and digital transformation to charities, NGOs, and enterprise customers, promotes Ellie Copp to Chief Revenue Officer.
Pracedo announced Ellie Copp as its new Chief Revenue Officer (CRO). Ellie joined Pracedo in 2019 and most recently held the position of Sales and Marketing Director. As CRO, she will continue to lead the commercial teams by overseeing all revenue-generating activities as Pracedo continues…
Partnership factors in sponsor – CRO relationships
Drugs discovered today can realistically cost upwards of 900 million dollars and around 12 years of development to reach a market. CRO’s have been increasingly used by larger pharma to outsource their clinical research, allowing big pharma to shut down in-house R&D, in practice saving money.
There have been some issues however with the outsourcing of trials to CROs, including serious relationship break down with negative attitudes, failure to communicate…
